A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

Condition:   Triple Negative Breast Cancer Interventions:   Drug: Nanosomal Docetaxel Lipid Suspension (75 mg/m2);   Drug: Nanosomal Docetaxel Lipid Suspension (100 mg/m2);   Drug: Taxotere® (100 mg/m2) Sponsors:   Jina Pharmaceuticals Inc.;   Intas Pharmaceuticals Limited;   Lambda Therapeutic Research Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials